Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
Status:
Completed
Trial end date:
2020-03-09
Target enrollment:
Participant gender:
Summary
This was an open label, multi-center protocol for U.S. patients enrolled in the study of
ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone
receptor-positive, HER2-negative, high risk early breast cancer